Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker and SISCAPA Assay Technologies Announce Second-Phase Collaboration Agreement

Published: Monday, September 16, 2013
Last Updated: Monday, September 16, 2013
Bookmark and Share
The ongoing collaboration aims to exploit MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.

Bruker Corporation announced the start of a second-phase collaboration agreement with SISCAPA Assays Technologies, Inc. (SAT) at the 12th HUPO World Congress.

Bruker and SAT’s first phase of collaboration resulted in two publications. The first paper, published in the Journal of Proteome Research, demonstrated that a SISCAPA-MALDI workflow showed quantitative precision equal to or better than SISCAPA LC-MS/MS workflows, with the improved ease of use that comes from eliminating the need for LC and MS/MS. The second paper, published in the journal Clinical Chemistry, validated the quantitative precision for a larger cohort of samples of clinical relevance, measuring the endogenous levels of Protein C Inhibitor from serum samples of patients who had been treated for prostate cancer. A summary of this work will be presented in a poster at the 12thHuman Proteome Organization World Congress (HUPO).

Having confirmed the utility and quantitative precision of the SISCAPA-MALDI workflow, the second-phase collaboration will focus on a number of further developments involving the measurement of clinically useful biomarkers. All SISCAPA-MALDI assays are currently for research use only, and not for use in diagnostic procedures.

Bruker plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities, allowing interested customers to evaluate SISCAPA-MALDI instrumentation and workflows. The demo facility will also enable high-level applications and service support for such customers by Bruker personnel.

Assay Development: Additional SISCAPA assays will be validated and parameters, such as the limit of quantitation and limit of detection (LOQ/LOD), will be determined. Bruker and SAT also plan to enable third-party collaborators to develop SISCAPA-MALDI assays for accurate quantification of their own protein targets, for use in RUO and clinical research environments. Such assays would be useful for a diverse range of customers, e.g. those wishing to pursue protein quantitation for process optimization or large-scale clinical validation of protein biomarkers. Bruker and SAT also jointly plan to investigate the development of new assays for the SISCAPA-MALDI workflow. Of particular interest are assays of relevance to clinical microbiology, as the previous work has shown that such assays could be run on the benchtopmicroflex LT, the same mass spectrometer employed in the Bruker MALDI Biotyper. Successful validation and clearance for clinical use of such assays would immediately make them available to the more than 900 (and growing) clinical microbiology laboratories worldwide that already have a MALDI Biotyper installed.

Leigh Anderson, Ph.D., the CEO and founder of SAT, and inventor of SISCAPA, commented: “We are delighted to be working with Bruker, the leader in MALDI-TOF technology, to advance the precision and throughput of SISCAPA biomarker assays. Our joint papers demonstrate the very high precision of MALDI-TOF mass spectrometry for peptide quantitation using internal standards, and establish a solid basis for further exploring the utility of SISCAPA-MALDI-TOF MS in biomarker verification and preclinical research. As a company devoted to the development and application of SISCAPA assays, we are excited that Bruker is making the investment to bring the SISCAPA-MALDI workflow into its demonstration facilities, and that this will increase of the productivity of labs using SISCAPA and spur the adoption of SISCAPA assays by the biomarker research community.”

Dr. Detlev Suckau, Director of Proteomics at Bruker Daltonics, added: “The results of the joint work prove that MALDI-TOF is very suitable for peptide and protein quantification in the one- to five-percent CV range, and also for the validation of protein biomarkers in clinical research. With the early phase of this research completed, Bruker has the confidence in SAT and SISCAPA-MALDI MS to make a significant investment needed to bring the fully automated SISCAPA-MALDI MS workflow into our demonstration facilities. This will enableBruker, in partnership with SAT, to sell SISCAPA-MALDI MS to customers and to support the many enthusiastic early adopters who have expressed interest in this technology.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker and 3M Sign Exclusive Patent License Agreement
The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin.
Tuesday, June 04, 2013
Bruker and SCiLS GmbH Announce an Exclusive Partnership
SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets.
Wednesday, May 15, 2013
Bruker and the Genome British Columbia Proteomics Centre to Collaborate
The collaborative effort covers the development and validation of high-throughput assays for determining hemoglobin variants and diabetes risk.
Thursday, April 18, 2013
Bruker and Erasmus Medical Center Sign an Exclusive Licensing Agreement
Agreement for adding rapid beta-lactamase testing capabilities to the MALDI Biotyper system.
Friday, January 04, 2013
Bruker and JMI Laboratories Announce Collaboration for Mass Spectrometry
The collaboration sees Bruker and JMI Laboratories partner in the field of fungal identification by proteomics fingerprinting.
Wednesday, June 20, 2012
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker and Berkeley Lab Collaborate on Novel Technology for Structural Biology
Berkeley Lab and Bruker intend to integrate SAXS and NMR data for 3D structure determination of multi-domain proteins and protein complexes with DNA, RNA or other proteins.
Thursday, November 24, 2011
Scientific News
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Thousands of Protein Interactions Identified
Thanks to the work by Utrecht University researcher Fan Liu and her colleagues, it is now possible to map the interactions between proteins in human cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos